Status:
UNKNOWN
A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
Lead Sponsor:
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
Conditions:
Osteosarcoma
Eligibility:
All Genders
12-60 years
Phase:
PHASE2
Brief Summary
Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.
Eligibility Criteria
Inclusion
- Patients with histologically confirmed osteosarcoma, who have no evidence of metastasis
- At least one measurable lesion
- Life expectancy \> 3 months
- ECOG performance status 0-2
- Adequate hematologic, cardiac, renal, and hepatic function
- Patients with prior chemotherapy should have at least 4 weeks clearance period before entering this study
Exclusion
- Evidence of metastasis
- Serious infection
- Evidence of bleeding diathesis
- Significant cardiovascular disease
- Pregnant or lactating woman
- Allergic to E.coli preparation
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01002092
Start Date
February 1 2009
End Date
December 1 2014
Last Update
September 3 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing General Hospital of Nanjing Military Command
Nanjing, Jiangsu, China, 210002
2
General Hospital of Jinan Military Command
Jinan, Shandong, China, 250031
3
Xijing Hospital
Xi’an, Shanxi, China, 710032
4
The Military General Hospital of Beijing PLA
Beijing, China, 100700